Log in or register to see all Alerts
New HTA Decisions in England
May 2021
Drug name
STAQUIS (crisaborole)
Company
Pfizer
Decision date
//
Therapeutic area
Skin conditions
Therapeutic sub area
Eczema
Decision
Not recommended
Indication
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because the company withdrew its evidence submission. The company has confirmed that it does not wish to make an evidence submission for the appraisal because currently the technology will not be launched in the UK. NICE will review this decision if the company decides to make a submission.